Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
Go back to Leerink Partners Reiterates Outperform Rating on Aurinia Pharmaceuticals (AUPH)
June 30, 2025 1:09 PM EDT
TD Cowen analyst Stacy Ku reiterated a Buy rating and $11.00 price target on Aurinia Pharmaceuticals (NASDAQ: AUPH).
The analyst comments "Phase I healthy volunteer SAD data for aritinercept/AUR200 (BAFF/April inhibitor) appear to be matching other competitive/BIC programs in development. Specifically, a single dose of aritinercept demonstrated max reduction from baseline of 20% for IgG, 48% for IgA, and 55% IgM at 225mg dose, and effects appear saturated at higher doses (225/300mg; details below). The PK/PD profile supports monthly subcutaneous dosing (half-life 6-8 days) - with... More
June 30, 2025 6:01 AM EDT
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive results from a Phase 1 single-ascending-dose (SAD) study of aritinercept (AUR200), its dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL). The study investigated aritinercept doses of 5 mg, 25 mg, 75 mg, 150 mg, 225 mg and 300 mg and placebo, administered by subcutaneous injection, in 61 healthy subjects.
Aritinercept was well tolerated at all dose levels tested. There were no treatment-related Grade 3 adverse... More
